Modus Therapeutics Holding Ab · OMXSTO:MODTX
Modus Therapeutics Holding Ab — Q4 2024 Earnings Presentation
26 slides from Modus Therapeutics Holding Ab's earnings presentation, Feb 19, 2025
Slide 1: Modus Therapeutics Year-End Report January-December 2024
MODUS THERAPEUTICS YEAR-END REPORT January - December 2024 1 2024
Slide 2: The Quarter in Brief
THE QUARTER IN BRIEF | JANUARY 1 - DECEMBER 31 2O24 YEAR-END REPORT 2024 The fourth quarter in figures Important events during the fourth quarter Important events after the end of the period • The loss after tax amounted to TSEK 4 713 • Modus Therapeutics receives a recruitment • Modus Therapeutics
Slide 3: CEO Statement: A year of transformation and new horizons
CEO STATEMENT A year of transformation and new horizons in patient care as Modus strengthens its pipeline 2024 has been a pivotal year for Modus Therapeutics, marked by significant clinical and scientific progress, key financing milestones, and new research insights shaping the future of patient car
Slide 4: CEO Statement (continued)
CEO STATEMENT Maitland, in bringing this trial closer to com- point for sevuparin in targeting a treatment • Continuing research collaborations and pletion. Given the increasing concerns over start early in the septic reaction, with a hig- communications to further validate sevupa- climate change’s
Slide 5: About Modus Therapeutics
STATEMENT OF OPERATIONS About Modus Therapeutics Modus is a Swedish biotechnology company that is developing its proprietary polysaccharide sevuparin as a potential treatment for several major healthcare needs including sepsis, endotoxemia, severe malaria and other disorders with severe systemic inf
Slide 6: Modus pipeline
STATEMENT OF OPERATIONS Modus pipeline INDICATION DEVELOPMENT Preclinical Phase Ia Phase Ib Phase IIa Phase IIb Phase III Sepsis Modus Sepsis/Septic chock Planning Phase IIa Anemia* Modus Anemia chronic inflammation/kidney disease Phase II a initiated Dec 2024 Malaria Collaboration** Severa malaria
Slide 7: Preclinical research suggests that sevuparin...
STATEMENT OF OPERATIONS These robust results from preclinical cellular and ani- mal models as well as human subjects demonstrate sevuparin’s ability to suppress hepcidin at clinically safe dose levels and provide strong evidence of its ability to modulate hepcidin expression. In addition, data from
Slide 8: Completed studies support phase 2 development in sepsis and anemia
STATEMENT OF OPERATIONS Completed studies support phase 2- Plasma hepcidin development in sepsis and anemia in decreased to 30-50% of baseline values chronic disease in the presence of Sevuparin, with maximal Sevuparin has been shown to be safe and tolerable with single and multiple suppression betw
Slide 9: Market overview
STATEMENT OF OPERATIONS Market overview With sevuparin, Modus primarily target three challanging indications - sepsis, anemia and severe malaria. Sevuparin has significant potential within the markets for these indication, which are mainly driven by the significant medical need and the increasing gl
Slide 10: Anemia in chronic kidney disease
STATEMENT OF OPERATIONS Anemia in chronic kidney disease Anemia is a global health issue affecting approxi- mately 2.3 billion people, which represents 25% of the world’s population. The most common form of anemia is iron deficiency anemia, impacting nearly one billion individuals. Chronic kidney di
Slide 11: Severe malaria
STATEMENT OF OPERATIONS Severe malaria Severe malaria is a rapidly progressing and serious condition resembling sepsis, primarily affecting young children, with a mortality rate of 10-20%. While available standard treatments are effective given time to start working, there is a lack of an adjuvant t
Slide 12: Development of profit and financial position
FINANCIAL REPORT Development of profit and financial position Fourth quarter Full year Operating profit/loss Operating profit/loss The operating loss for the period October– The operating loss for the period January– December 2024 amounted to 4,846 (3,772) December 2024 amounted to 15,838 TSEK. Rese
Slide 13: Important events during the quarter
FINANCIAL REPORT Important events during to SEK 5.0 million from its largest shareholder, Karolinska Development. These results reinforce sevuparin’s potential the quarter in treating conditions with high unmet The access to this funding enables Modus medical need. Modus Therapeutics receives a recr
Slide 14: Important events during and after the quarter (cont.)
FINANCIAL REPORT Important events during Important events after the quarter cont. the end of the quarter Modus Therapeutics receives a recruitment Modus Therapeutics Presents LPS Study update from the collaborative Phase Ib Data at Pharmacology 2024 study in severe malaria On December 10, Modus Ther
Slide 15: Other disclosures
FINANCIAL REPORT Other disclosures Ownership structure 740(740). The loss for the period amounted via the Company’s website (www.modustx. At the end of the fourth quarter, there were to TSEK 14 968 (15 187). The company’s net com) on April 15, 2025 948 shareholders in Modus Therapeutics sales consis
Slide 16: Financial report: financing and risks
FINANCIAL REPORT 9,682,280 shares were subscribed for and There are no guarantees that the required ca- The Board monitors the evolvement of the the subscription price in the Rights Issue pital can be raised to finance the developme- crises closely and Modus is working intensi- was SEK 2.00 per shar
Slide 17: Consolidated summary income statement
FINANCIAL REPORT Consolidated summary income statement 2024 2023 2024 2023 TSEK Oct 1 - Dec 31 Oct 1 - Dec 31 Jan 1 - Dec 31 Jan 1 - Dec 31 Net sales - - - - Research and development costs -2 853 -1 239 -9 067 -8 482 Administration costs -1 978 -2 535 -6 727 -7 832 Other operating expenses -15 2 -44
Slide 18: Consolidated summary balance sheet
FINANCIAL REPORT Consolidated summary balance sheet 2024 2023 TSEK Dec 31 Dec 31 Assets Fixed assets Other financial fixed assets 52 51 Total fixed assets 52 51 Current assets Other receivables 453 930 Cash equivalents 4 379 19 060 Total current assets 4 832 19 990 TOTAL ASSETS 4 884 20 041 Equity a
Slide 19: Consolidated change in shareholders' equity in summary
FINANCIAL REPORT Consolidated change in shareholder’s equity in summary 2024 2023 2024 2023 TSEK Oct 1 - Dec 31 Oct 1 - Dec 31 Jan 1 - Dec 31 Jan 1 - Dec 31 Opening balance equity 6 850 -16 414 17 681 -2 585 Profit/loss for the period -4 713 -4 069 -15 545 -17 897 Total comprehensive income -4 713 -
Slide 20: Consolidated cash flow statement in summary
FINANCIAL REPORT Consolidated cash flow statement in summary 2024 2023 2024 2023 TSEK Oct 1 - Dec 31 Oct 1 - Dec 31 Jan 1 - Dec 31 Jan 1 - Dec 31 Operating activities Operating profit/loss -4 846 -3 771 -15 838 -16 401 Interest received 132 2 292 3 Interest paid - - - - Cash flow from operating acti
Slide 21: Parent company income statement in summary
FINANCIAL REPORT Parent company income statement in summary 2024 2023 2024 2023 TSEK Oct 1 - Dec 31 Oct 1 - Dec 31 Jan 1 - Dec 31 Jan 1 - Dec 31 Net sales 185 185 740 740 Research and development costs -506 -411 -1 591 -1 419 Administration costs -1 627 -2 270 -5 969 -6 587 Other operating expenses
Slide 22: Parent company balance sheet in summary
FINANCIAL REPORT Parent company balance sheet in summary 2024 2023 TSEK Dec 31 Dec 31 Assets Non-current assets Financial assets 70 052 70 051 Total non-current assets 70 052 70 051 Current assets Other receivables 162 762 Cash equivalents 2 519 18 381 Total current assets 2 681 19 143 TOTAL ASSETS
Slide 23: Notes to the financial reports in summary
FINANCIAL REPORT Notes to the financial reports in summary Note 1 | Accounting principles Note 3 | Incentive program Note 4 | Equity Modus Therapeutics Holding AB’s consoli- The ”Incentive Program 2021/2024” has The share capital of the Parent Company dated accounts have been prepared in expired. No
Slide 24: Financial calendar and signatures
FINANCIAL REPORT Financial calendar Signatures The Board of Directors and the CEO provide their assurance that this interim Annual Report 2024 report provides an accurate view of the operations, position and earning of the | April 15th, 2025 group and the parent company, and that it also describes t
Slide 25: Quarterly overview and definitions
FINANCIAL REPORT Quarterly overview 2024 2023 THE GROUP Q4 Q3 Q2 Q1 Q4 Q3 Q2 Q1 Net sales, TSEK - - - - - - - - Operating profit, TSEK -4 846 -2 989 -4 804 -3 199 -3 771 -2 456 -4 365 -5 808 Equity/Asset ratio, % 44% 80% 79% 91% 88% -311% -238% -117% Cash equivalents, TSEK 4 379 7 999 11 971 15 395
Slide 26: Contact
CONTACT Olof Palmes gata 29 IV John Öhd, CEO 111 22 Stockholm +46(0)70-766 80 97 Sweden john.ohd@modustx.com +46(0)8-502 492 53 Claes Lindblad, CFO & Head of IR ir@modustx.com +46(0)70-246 75 54 www.modustx.com ir@modustx.com 26
Modus Therapeutics Holding — Q4 2024 Earnings Presentation on 6ix